RCT for the Chinese Medicine in Treating Hypercholesterolemia

NCT ID: NCT06700408

Last Updated: 2024-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-31

Study Completion Date

2027-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, placebo-controlled clinical trial. Eligible subjects will randomized into a treatment group or placebo group. They will receive either Chinese medicine granules or placebo granules for 8 weeks followed by a 4-week observation period. The primary outcome would be the percent change in Low-density lipoprotein cholesterol levels (LDL-C) after treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypercholesterolemia refers to a metabolic disease caused by abnormal cholesterol metabolism in the blood cholesterol content exceeding the normal range, which can be mainly divided into total cholesterol (TC) in plasma and low-density lipoprotein cholesterol LDL-C) or a decrease in high-density lipoprotein cholesterol (HDL-C). Uncontrolled hypercholesterolemia is considered an important risk factor for cardiovascular and cerebrovascular diseases.

In recent years, there has been an increasing number of clinical studies of Traditional Chinese Medicine combinations or single herbs for hypercholesterolemia, and some drugs do have cholesterol-lowering effects, but the clinical evidence is not high due to bias or other deficiencies in trial design. Therefore, this clinical trial aim to evaluate the effectiveness of Dachaihu Decoction combined Erzhiwan with variation to the treatment of patients with clinical hypercholesterolemia, and tried to reduce its adverse effects on liver function through reasonable compatibility.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dachaihu Decoction combined Erzhiwan with variation granules

Chinese medicine granules

Group Type EXPERIMENTAL

Dachaihu Decoction combined Erzhiwan with variation

Intervention Type DRUG

Chinese medicine granules

Placebo granules

Placebo granules

Group Type PLACEBO_COMPARATOR

Placebo granules

Intervention Type OTHER

Placebo granules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dachaihu Decoction combined Erzhiwan with variation

Chinese medicine granules

Intervention Type DRUG

Placebo granules

Placebo granules

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Chinese medicine granules

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-80 years old, any gender;
* LDL-C level of 4.1 mmol/L or above (no statin therapy during the screening period);
* Be able to maintain a more consistent lifestyle and eating habits throughout the study;
* Have a fixed residence and are not expected to move or travel for 8 weeks;
* Voluntarily sign the informed consent form.

Exclusion Criteria

* Taking drugs that may affect lipid metabolism (such as steroids, sleeping pills, and psychotropic drugs);
* Alcohol or drug abuse within the last 3 months;
* Known liver function or renal dysfunction;
* History of severe cardiovascular and cerebrovascular diseases; or history of psychiatric illness;
* Participate in other interventional clinical trials within 3 months before the study, including drugs, supplements, medical devices, etc.;
* Known pregnant or lactating women, allergies or allergies to traditional Chinese medicine;
* Patients with known secondary hypercholesterolemia.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese University of Hong Kong

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. Lin Zhixiu

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zhixiu Lin, Prof

Role: PRINCIPAL_INVESTIGATOR

Chinese University of Hong Kong

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zhixiu Lin, Prof

Role: CONTACT

Cho Wing Lo

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Hypercholesterolemia study

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CHM for T2DM & MetS
NCT06450652 NOT_YET_RECRUITING NA